

Appl. No. 10/773,083  
Amdt. dated August 8, 2005

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

Claims 1-20 (cancelled)

**Claim 21 (new)** A method of treating an IL-23 mediated disorder comprising administering an effective amount of an antagonist of IL-23, wherein the antagonist is an antigen binding fragment of an antibody or a soluble receptor derived from IL-23 receptor (IL-23R).

**Claim 22 (new)** The method of Claim 1 wherein the disorder is a gastrointestinal disorder.

**Claim 23 (new)** The method of Claim 1, wherein the antibody is:

- a) a polyclonal antibody;
- b) a monoclonal antibody;
- c) a humanized antibody;
- d) detectably labeled

**Claim 24 (new)** The method of Claim 1, wherein the antigen binding fragment of the antibody is:

- a) humanized; or
- b) an Fab, Fv, or F(ab')2 fragment.

**Claim 25 (new)** The method of Claim 1, wherein the IL-23 mediated disorder is an inflammatory bowel disorder.

Appl. No. 10/773,083  
Am dt. dated August 8, 2005

Claim 26 (new) The method of Claim 25, wherein the inflammatory bowel disorder is:

- a) Crohn's disease
- b) Ulcerative colitis
- c) Celiac disease

Claim 27 (new) The method of Claim 25, wherein the inflammatory bowel disorder results in mucosal thickening, epithelial hyperplasia, inflammation of the submucosa or tunica muscularis, or infiltration by granulocytes or macrophages.

Claim 28 (new) The method of Claim 1, wherein the antagonist of IL-23 inhibits:

- a) expression of IL-1 $\beta$  by a macrophage; or
- b) expression of TNF $\alpha$  by a macrophage.